Investigation on weight change in schizophrenia patients induced by olanzapine under guidance of gene detection
-
摘要: 目的 探讨奥氮平对精神分裂症患者体质量的影响。 方法 给予5-羟色胺受体2C(5-HTR2C)(-759 C>T)基因型为TT和TC的27例患者奥氮平治疗,比较治疗前和治疗12周后患者体质量、Qvetelet体质量指数、血糖、血脂变化,以及治疗前和治疗2、4、8、12周后患者阳性与阴性症状量表(PANSS)评分。 结果 治疗12周后,本组患者体质量增加,与治疗前比较差异有统计学意义(P<0.01); Qvetelet体质量指数增加(7.00±2.66)%, 与治疗前比较差异无统计学意义(P>0.05); 本组患者治疗前后的血糖、胆固醇、甘油三酯、高密度脂蛋白及低密度脂蛋白比较,差异无统计学意义(P>0.05)。奥氮平治疗2周后,本组患者PANSS量表阳性症状、阴性症状、一般症状评分及PANSS总分与治疗前比较,差异均有统计学意义(P<0.01)。 结论 奥氮平能有效改善精神分裂症患者的精神症状,而医务人员应重视该药引起的体质量增加等不良反应,积极采取早期预防措施,提高患者的治疗依从性和生活质量。Abstract: Objective To explore the effect of olanzapine on weight in schizophrenic patients. Methods Totally 27 patients with genotype TT and TC of 5-hydroxytryptamine type 2C receptor(5-HTR2C)(-759 C>T)were treated by olanzapine. The changes of body mass, Qvetelet body mass index, blood glucose and blood lipid were compared before treatment and 12 weeks after treatment as well as scores of Positive and Negative Symptom Scale(PANSS)before treatment and 2, 4, 8, 12 weeks after treatment were compared. Results After 12 weeks of treatment, the body weight of patients increased significantly when compared to that before treatment(P<0.01), while Qvetelet body mass index increased by(7.00±2.66)%, but there was no significant difference before and after treatment(P>0.05). There were no significant differences in blood glucose, cholesterol, triglyceride, high density lipoprotein and low density lipoprotein before and after treatment(P>0.05). After 2 weeks of olanzapine treatment, the scores of positive symptoms, negative symptoms and general symptom of PANSS as well as total score were significant different from those before treatment(P<0.01). Conclusion Olanzapine can effectively improve the mental symptoms of patients with schizophrenic. Medical staffs should pay attention to the adverse reactions caused by olanzapine such as weight gain, and actively take early preventive measures to improve the therapeutic compliance and quality of life of patients.
-
-
LAURSEN T M, WAHLBECK K, HÄLLGREN J, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries[J]. PLoS One, 2013, 8(6): e67133.
蔡东滨, 杨欣湖, 郑伟, 等. 预防抗精神病药物所致首发精神分裂症患者体质量增加的研究现况[J]. 四川精神卫生, 2017, 30(2): 191-195. LUAN S X, WAN H Q, WANG S J, et al. Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials[J]. Neuropsychiatr Dis Treat, 2017, 13: 609-620.
ZIVKOVIC N, DJOKIC G, BAJOVIC B, et al. 1431-Effect of cigarette smoking in male patients with schizophrenia treated with olanzapine[J]. Eur Psychiatry, 2013, 28: 1-10.
王玮, 李宪伟. 精神分裂症90例基因检测回顾性分析[J]. 精神医学杂志, 2016, 29(6): 448-450. BARAK N, BECK Y, ALBECK J H. A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain[J]. J Clin Psychopharmacol, 2016, 36(3): 253-256.
TEK C, KUCUKGONCU S, GULOKSUZ S, et al. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications[J]. Early Interv Psychiatry, 2016, 10(3): 193-202.
姚志剑, 张志, 张晓斌, 等. 抗精神病药物所致体质量增加与多巴胺D2受体基因多态性和治疗效应的关联分析[J]. 江苏医药杂志, 2002, 28(11): 801-803. 郭蕊, 张晋萍, 丁选胜, 等. 基因多态性与奥氮平临床疗效相关性的研究进展[J]. 中国药房, 2017, 28(35): 5024-5028. 董文凤, 姚树永, 曹敏娟, 等. 第二代抗精神病药物奥氮平致代谢失衡的干预措施研究进展[J]. 中国医药导报, 2018, 15(4): 43-46. 付艳梅, 陈尚周. 二甲双胍治疗抗精神病药物所致体质量增加和血糖异常的研究进展[J]. 四川医学, 2017, 12(38): 1451-1453. 袁日强, 钟远惠, 刘舜华, 等. 药物结合心理行为的综合干预对精神分裂症伴代谢综合征患者代谢指标影响的研究[J]. 中国医学创新, 2016, 13(16): 13-16.
计量
- 文章访问数: 417
- HTML全文浏览量: 112
- PDF下载量: 13
下载:
苏公网安备 32100302010246号
